NEW YORK (GenomeWeb) – Veracyte today said that it has signed a partnership with Fleury Medicine and Health to make its Afirma Gene Expression Classifier for thyroid cancer diagnosis available to patients in Brazil.

Fleury will exclusively offer the Afirma GEC through its diagnostics centers across Brazil. The genomic test will be offered when patients' thyroid nodule fine needle aspiration results are indeterminate following cytopathology review.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.